Table 2.
Results of univariate and multivariate analyses
| Predictor | Hazard ratio (HR) | 95% confidence interval (CI) | p value |
|---|---|---|---|
| Univariate Cox regression analysis for overall survival calculated from ibrutinib initiation | |||
| Female sex (versus male) | 0.53 | 0.29, 0.98 | 0.076 |
| Ki67 ≥ 30% (versus < 30%) | 2.2 | 1.00, 4.82 | 0.04 |
| Ann Arbor clinical stage before ibrutinib | |||
| I | Reference | ||
| II | 1.05 | 0.28, 3.89 | 0.9 |
| III | 0.72 | 0.18, 2.93 | 0.6 |
| IV | 1.14 | 0.43, 3.04 | 0.8 |
| MIPI | |||
| Low risk | Reference | — | |
| Intermediate risk | 1.07 | 0.37, 3.08 | 0.9 |
| High risk | 0.95 | 0.38, 2.34 | 0.9 |
| First line regimen | |||
| CHOP/CHOP-like | Reference | ||
| High-dose cytarabine regimen | 0.70 | 0.38, 1.27 | 0.2 |
| Non-anthracycline regimen | 0.79 | 0.37, 1.71 | 0.6 |
| ASCT, yes (versus no) | 1.21 | 0.65, 2.28 | 0.5 |
| Rituximab maintenance yes (versus no) | 1.05 | 0.60, 1.81 | 0.9 |
| Treatment response to first line | |||
| SD + PD | Reference | ||
| PR | 0.89 | 0.40, 1.98 | 0.8 |
| CR/CRu | 0.86 | 0.40, 1.84 | 0.7 |
| POD after first line (continuous) | 0.99 | 0.98, 1.00 | 0.2 |
| POD12, yes (versus no) | 1.53 | 0.78, 2.99 | 0.16 |
| POD24, yes (versus no) | 1.42 | 0.82, 2.47 | 0.2 |
| POD36, (versus no) | 0.99 | 0.52, 1.86 | 0.97 |
| BM involvement before ibrutinib, yes (versus no) | 0.65 | 0.32, 1.32 | 0.23 |
| Lines before ibrutinib, 1 vs. 2 and more | 0.49 | 0.27, 0.87 | 0.035 |
| Treatment response to ibrutinib | |||
| SD + PD | Reference | ||
| PMR | 0.56 | 0.30, 1.06 | 0.074 |
| CMR | 0.24 | 0.11, 0.52 | < 0.001 |
| Univariate Cox regression analysis for overall survival calculated from diagnosis | |||
| Female sex (versus male) | 0.83 | 0.40, 1.71 | 0.6 |
| Ki67 ≥ 30% (versus < 30%) | 2.56 | 1.03, 6.37 | 0.044 |
| Ann Arbor clinical stage | |||
| I | Reference | ||
| II | 0.51 | 0.12, 2.07 | 0.3 |
| III | 0.88 | 0.22, 3.56 | 0.9 |
| IV | 0.97 | 0.34, 2.77 | > 0.9 |
| MIPI | |||
| Low risk | Reference | — | |
| Intermediate risk | 2.88 | 0.72, 11.6 | 0.14 |
| High risk | 3.71 | 1.07, 12.9 | 0.039 |
| First line regimen | |||
| CHOP/CHOP-like | Reference | — | |
| High-dose cytarabine regimen | 0.96 | 0.51, 1.81 | 0.9 |
| Non-anthracycline regimen | 0.74 | 0.32, 1.70 | 0.5 |
| ASCT, yes (versus no) | 1.39 | 0.75, 2.55 | 0.3 |
| Rituximab maintenance yes (versus no) | 1 | 0.56, 1.77 | > 0.9 |
| Treatment response to first line | |||
| SD + PD | Reference | ||
| PR | 0.28 | 0.12, 0.68 | 0.005 |
| CR/CRu | 0.15 | 0.06, 0.36 | < 0.001 |
| POD after first line (continuous) | 0.98 | 0.97, 0.99 | 0.002 |
| POD12, yes (versus no) | 2.99 | 1.64, 5.45 | < 0.001 |
| POD24, yes (versus no) | 2.87 | 1.57, 5.22 | < 0.001 |
| POD36, yes (versus no) | 2.08 | 1.07, 4.04 | 0.03 |
| BM involvement before ibrutinib yes (versus no) | 0.65 | 0.33, 1.28 | 0.2 |
| Lines before ibrutinib | 0.76 | 0.62, 0.94 | 0.013 |
| Treatment response to ibrutinib | |||
| SD + PD | Reference | ||
| PMR | 0.77 | 0.41, 1.46 | 0.4 |
| CMR | 0.39 | 0.18, 0.88 | 0.022 |
| Multivariate Cox regression analysis for overall survival calculated from ibrutinib initiation | |||
| Lines before ibrutinib | 0.55 | 0.31, 0.95 | 0.032 |
| Ki67 ≥ 30% (versus < 30%) | 2.73 | 1.04, 7.15 | 0.042 |
MIPI, Mantle Cell Lymphoma International Prognostic Index; ASCT, autologous stem cell transplant; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; CMR, complete metabolic remission; PMR, partial metabolic remission; POD, progression of disease; BM, bone marrow